Cargando…
Acid Sphingomyelinase Inhibition Stabilizes Hepatic Ceramide Content and Improves Hepatic Biotransformation Capacity in a Murine Model of Polymicrobial Sepsis
Liver dysfunction during sepsis is an independent risk factor leading to increased mortality rates. Specifically, dysregulation of hepatic biotransformation capacity, especially of the cytochrome P450 (CYP) system, represents an important distress factor during host response. The activity of the con...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214114/ https://www.ncbi.nlm.nih.gov/pubmed/30326559 http://dx.doi.org/10.3390/ijms19103163 |
_version_ | 1783367927980883968 |
---|---|
author | Chung, Ha-Yeun Witt, C. Julius Hurtado-Oliveros, Jorge Wickel, Jonathan Gräler, Markus H. Lupp, Amelie Claus, Ralf A. |
author_facet | Chung, Ha-Yeun Witt, C. Julius Hurtado-Oliveros, Jorge Wickel, Jonathan Gräler, Markus H. Lupp, Amelie Claus, Ralf A. |
author_sort | Chung, Ha-Yeun |
collection | PubMed |
description | Liver dysfunction during sepsis is an independent risk factor leading to increased mortality rates. Specifically, dysregulation of hepatic biotransformation capacity, especially of the cytochrome P450 (CYP) system, represents an important distress factor during host response. The activity of the conserved stress enzyme sphingomyelin phosphodiesterase 1 (SMPD1) has been shown to be elevated in sepsis patients, allowing for risk stratification. Therefore, the aim of the present study was to investigate whether SMPD1 activity has an impact on expression and activity of different hepatic CYP enzymes using an animal model of polymicrobial sepsis. Polymicrobial sepsis was induced in SMPD1 wild-type and heterozygous mice and hepatic ceramide content as well as CYP mRNA, protein expression and enzyme activities were assessed at two different time points, at 24 h, representing the acute phase, and at 28 days, representing the post-acute phase of host response. In the acute phase of sepsis, SMPD1(+/+) mice showed an increased hepatic C16- as well as C18-ceramide content. In addition, a downregulation of CYP expression and activities was detected. In SMPD1(+/−) mice, however, no noticeable changes of ceramide content and CYP expression and activities during sepsis could be observed. After 28 days, CYP expression and activities were normalized again in all study groups, whereas mRNA expression remained downregulated in SMPD(+/+) animals. In conclusion, partial genetic inhibition of SMPD1 stabilizes hepatic ceramide content and improves hepatic monooxygenase function in the acute phase of polymicrobial sepsis. Since we were also able to show that the functional inhibitor of SMPD1, desipramine, ameliorates downregulation of CYP mRNA expression and activities in the acute phase of sepsis in wild-type mice, SMPD1 might be an interesting pharmacological target, which should be further investigated. |
format | Online Article Text |
id | pubmed-6214114 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-62141142018-11-14 Acid Sphingomyelinase Inhibition Stabilizes Hepatic Ceramide Content and Improves Hepatic Biotransformation Capacity in a Murine Model of Polymicrobial Sepsis Chung, Ha-Yeun Witt, C. Julius Hurtado-Oliveros, Jorge Wickel, Jonathan Gräler, Markus H. Lupp, Amelie Claus, Ralf A. Int J Mol Sci Article Liver dysfunction during sepsis is an independent risk factor leading to increased mortality rates. Specifically, dysregulation of hepatic biotransformation capacity, especially of the cytochrome P450 (CYP) system, represents an important distress factor during host response. The activity of the conserved stress enzyme sphingomyelin phosphodiesterase 1 (SMPD1) has been shown to be elevated in sepsis patients, allowing for risk stratification. Therefore, the aim of the present study was to investigate whether SMPD1 activity has an impact on expression and activity of different hepatic CYP enzymes using an animal model of polymicrobial sepsis. Polymicrobial sepsis was induced in SMPD1 wild-type and heterozygous mice and hepatic ceramide content as well as CYP mRNA, protein expression and enzyme activities were assessed at two different time points, at 24 h, representing the acute phase, and at 28 days, representing the post-acute phase of host response. In the acute phase of sepsis, SMPD1(+/+) mice showed an increased hepatic C16- as well as C18-ceramide content. In addition, a downregulation of CYP expression and activities was detected. In SMPD1(+/−) mice, however, no noticeable changes of ceramide content and CYP expression and activities during sepsis could be observed. After 28 days, CYP expression and activities were normalized again in all study groups, whereas mRNA expression remained downregulated in SMPD(+/+) animals. In conclusion, partial genetic inhibition of SMPD1 stabilizes hepatic ceramide content and improves hepatic monooxygenase function in the acute phase of polymicrobial sepsis. Since we were also able to show that the functional inhibitor of SMPD1, desipramine, ameliorates downregulation of CYP mRNA expression and activities in the acute phase of sepsis in wild-type mice, SMPD1 might be an interesting pharmacological target, which should be further investigated. MDPI 2018-10-15 /pmc/articles/PMC6214114/ /pubmed/30326559 http://dx.doi.org/10.3390/ijms19103163 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chung, Ha-Yeun Witt, C. Julius Hurtado-Oliveros, Jorge Wickel, Jonathan Gräler, Markus H. Lupp, Amelie Claus, Ralf A. Acid Sphingomyelinase Inhibition Stabilizes Hepatic Ceramide Content and Improves Hepatic Biotransformation Capacity in a Murine Model of Polymicrobial Sepsis |
title | Acid Sphingomyelinase Inhibition Stabilizes Hepatic Ceramide Content and Improves Hepatic Biotransformation Capacity in a Murine Model of Polymicrobial Sepsis |
title_full | Acid Sphingomyelinase Inhibition Stabilizes Hepatic Ceramide Content and Improves Hepatic Biotransformation Capacity in a Murine Model of Polymicrobial Sepsis |
title_fullStr | Acid Sphingomyelinase Inhibition Stabilizes Hepatic Ceramide Content and Improves Hepatic Biotransformation Capacity in a Murine Model of Polymicrobial Sepsis |
title_full_unstemmed | Acid Sphingomyelinase Inhibition Stabilizes Hepatic Ceramide Content and Improves Hepatic Biotransformation Capacity in a Murine Model of Polymicrobial Sepsis |
title_short | Acid Sphingomyelinase Inhibition Stabilizes Hepatic Ceramide Content and Improves Hepatic Biotransformation Capacity in a Murine Model of Polymicrobial Sepsis |
title_sort | acid sphingomyelinase inhibition stabilizes hepatic ceramide content and improves hepatic biotransformation capacity in a murine model of polymicrobial sepsis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214114/ https://www.ncbi.nlm.nih.gov/pubmed/30326559 http://dx.doi.org/10.3390/ijms19103163 |
work_keys_str_mv | AT chunghayeun acidsphingomyelinaseinhibitionstabilizeshepaticceramidecontentandimproveshepaticbiotransformationcapacityinamurinemodelofpolymicrobialsepsis AT wittcjulius acidsphingomyelinaseinhibitionstabilizeshepaticceramidecontentandimproveshepaticbiotransformationcapacityinamurinemodelofpolymicrobialsepsis AT hurtadooliverosjorge acidsphingomyelinaseinhibitionstabilizeshepaticceramidecontentandimproveshepaticbiotransformationcapacityinamurinemodelofpolymicrobialsepsis AT wickeljonathan acidsphingomyelinaseinhibitionstabilizeshepaticceramidecontentandimproveshepaticbiotransformationcapacityinamurinemodelofpolymicrobialsepsis AT gralermarkush acidsphingomyelinaseinhibitionstabilizeshepaticceramidecontentandimproveshepaticbiotransformationcapacityinamurinemodelofpolymicrobialsepsis AT luppamelie acidsphingomyelinaseinhibitionstabilizeshepaticceramidecontentandimproveshepaticbiotransformationcapacityinamurinemodelofpolymicrobialsepsis AT clausralfa acidsphingomyelinaseinhibitionstabilizeshepaticceramidecontentandimproveshepaticbiotransformationcapacityinamurinemodelofpolymicrobialsepsis |